Rosetta to Raise $2.2 Million in Registered Direct Offering
News May 18, 2012
Rosetta Genomics, Ltd. has announced that it has entered into definitive agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share in a registered direct offering.
The offering is expected to close on or about May 22, 2012, subject to the satisfaction of customary closing conditions.
Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.
Aegis Capital Corp. acted as the exclusive placement agent for the offering.
A shelf registration statement relating to the securities offered and sold in the offering has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective.
A final prospectus supplement relating to the offering will be filed by Rosetta with the SEC.
Copies of the final prospectus supplement and accompanying prospectus may be obtained directly from Rosetta by contacting Rosetta Genomics Ltd., 10 Plaut Street, Science Park, Rehovot 76706, Israel or via telephone at 215-382-9000 ext. 309.
The days - or even weeks - spent waiting for the results of a cancer-screening test can feel like an eternity. Especially when early diagnosis and quick action are tied to better outcomes. Now, a new technique to analyze proteins expressed on cancer cells shows promise in more rapidly detecting these cell types.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019